The UK glucose insulin in stroke trial (GIST-UK) also failed to demonstrate a benefit in all-cause mortality and death or disability at 90 days with glucose-potassium-insulin (GKI) infusion in hyperglycemic patients [129]. The gene discussed is INS; the disease is stroke disorder.